Results from TTK clinical trials have recently been published, and some adverse effects (severe anemia, fatigue, and neutropenia at the highest doses) were reported with combined treatments with TTK inhibitor S81694 [70], or with Paclitaxel and TTK inhibitor BAY1217389 [71] in patients with diverse solid tumors. This evidence concerns the gene TTK and anemia.